Nuvation Bio Inc. (NUVB) vs Recursion Pharmaceuticals, Inc. (RXRX)

Nuvation Bio Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Nuvation Bio Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.1B and $2.0B). Nuvation Bio Inc. grew revenue faster over the last twelve months: 1,083.6% against −15.1%. Nuvation Bio Inc. has the higher net margin (−88.2% vs −945.9%) and the higher return on invested capital (0.00% vs −92.2%). Across the 17 metrics below, Nuvation Bio Inc. leads on 14 and Recursion Pharmaceuticals, Inc. on 3.

Valuation

Metric NUVB RXRX Biotechnology median
P/E n/m n/m 7.88
P/S 11.78 36.30 11.47
P/B 7.89 2.18 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 9.36 26.34 10.73
Earnings yield (7.57%) (27.81%) (28.84%)
Free cash flow yield (6.04%) (17.79%) (23.03%)

Profitability

Metric NUVB RXRX Biotechnology median
Gross margin 88.18% 3.48% 65.16%
Operating margin (81.00%) (991.72%) 0.00%
Net margin (88.19%) (945.92%) 0.00%
Free cash flow margin (71.17%) (645.82%) 0.00%
Return on equity (47.81%) (56.58%) (57.72%)
Return on assets (21.53%) (41.26%) (49.22%)
Return on invested capital 0.00% (92.22%) 0.00%

Growth

Metric NUVB RXRX Biotechnology median
Revenue growth (TTM) 1,083.56% (15.08%) 5.64%
EPS growth (last fiscal year) 71.56% 14.79% —
Revenue growth, 5-year CAGR — 48.97% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NUVB RXRX Biotechnology median
Debt to equity 0.98 0.01 0.00
Current ratio 8.37 5.03 4.73
Net debt to EBITDA 2.26 1.31 0.96

Dividend

Metric NUVB RXRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric NUVB RXRX Biotechnology median
Market cap 2.02b 2.11b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack